Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Behçet Disease. At the time of diagnosis, subjects must meet the international study group criteria for Behçet Disease~* Females of childbearing potential (FCBP) must have negative pregnancy tests and agree to use two forms of contraception throughout the study.~* Males must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP~* Laboratory criteria: Hgb ≥ 9 g/dL, WBC count ≥ 3000 /microL and ≤14,000/microL, platelet count ≥ 100,000 /microL,, serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L), total bilirubin ≤ 2.0 mg/dL, AST and ALT ≤ 1.5 X ULN~* Two or more oral ulcers over the 28 day period before screening, with or without current treatment~* Two or more oral ulcers at the time of randomization (Visit 2, Baseline)~Exclusion Criteria:~* Pregnant or breast feeding~* Any condition which places the subject at risk~* Systemic fungal infection~* History of TB infection within 3 years~* History of recurrent bacterial infection~* Mycobacterium TB as indicated by a positive PPD skin test~* History of incompletely treated Mycobacterium tuberculosis~* Clinically significant chest x-ray abnormality at screening.~* Clinically significant ECG abnormality at screening~* History of HIV infection~* History of congenital or acquired immunodeficiency~* Hepatitis B surface antigen positive or Hepatitis B core antibody positive at screening~* Antibodies to Hepatitis C at screening~* History of malignancy (except for treated basal-cell skin carcinomas \> 3 years prior to screening)~* Any active major organ involvement of Behçet Disease~* Use of concomitant immune modulating therapy or topical corticosteroids.~* Use of ocular corticosteroids~* Use of any investigational medication within 4 weeks prior to randomization or 5 PK/PD half-lives (whichever is longer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A. Apremilast (Type: ACTIVE_COMPARATOR): None
- B. Placebo Comparator (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).